Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

NCT03155945 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT03155945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03155945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 19, 2017
Completion date
September 10, 2018
Enrollment
14 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

abdominal pain, crohn's disease